Turnstone Biologics (NASDAQ:TSBX) Issues Earnings Results

Turnstone Biologics (NASDAQ:TSBX) released its quarterly earnings results on Tuesday. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.13, Zacks reports.

Turnstone Biologics Stock Performance

Shares of TSBX stock opened at $0.53 on Thursday. Turnstone Biologics has a fifty-two week low of $0.44 and a fifty-two week high of $5.75. The firm has a market capitalization of $12.35 million, a price-to-earnings ratio of -0.16 and a beta of 2.21. The stock’s 50-day simple moving average is $0.54 and its 200-day simple moving average is $1.69.

Analysts Set New Price Targets

Several research firms recently commented on TSBX. Piper Sandler reduced their price objective on shares of Turnstone Biologics from $20.00 to $3.75 and set an “overweight” rating for the company in a research note on Monday, August 19th. Bank of America downgraded Turnstone Biologics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $10.00 to $0.50 in a research report on Monday, October 14th.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.